关于处于免治疗缓解期 (TFR) 的慢性粒细胞白血病 (CML) 患者的健康相关生活质量 (HRQoL) 和症状的数据有限。我们在此报告 EURO-SKI 试验的 HRQoL 结果。来自 11 个欧洲国家的接受酪氨酸激酶抑制剂 (TKI) 治疗至少 3 年且达到 MR4 至少 1 年的患者被纳入研究，并使用 EORTC QLQ-C30 和 FACIT-Fatigue 问卷来评估 HRQoL 和 FACIT-Fatigue 问卷。分别疲劳。患者被分为以下年龄组：18-39岁、40-59岁、60-69岁和≥70岁。在 728 名基线评估患者中，686 名 (94%) 完成了 HRQoL 评估。停用 TKI 时的中位年龄为 60 岁。我们的研究结果表明，HRQoL 和症状轨迹可能会因特定年龄组的不同而有所不同，其中年轻患者受益最多。 60 岁或以上患者在多个 HRQoL 和症状领域的改善微乎其微。在考虑停用 TKI 时，医生可以告知年轻患者，他们可能会获得宝贵的 HRQoL 益处。考虑到在 60 岁或以上患者中观察到的边际改善，进一步研究 TFR 与这一老年患者组中最低有效剂量方法相比的价值可能很重要。© 2024。作者，已获得独家许可施普林格自然有限公司。

Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18-39, 40-59, 60-69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.